Sei Investments Co. Has $48.55 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Sei Investments Co. increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,829,811 shares of the biopharmaceutical company's stock after purchasing an additional 94,124 shares during the period. Sei Investments Co.'s holdings in Pfizer were worth $48,545,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Swedbank AB increased its holdings in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock valued at $166,284,000 after purchasing an additional 37,636 shares during the last quarter. United Bank grew its stake in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock valued at $1,030,000 after buying an additional 1,277 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new position in Pfizer in the 3rd quarter valued at about $2,123,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Pfizer by 67.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company's stock worth $428,000 after acquiring an additional 5,959 shares during the last quarter. Finally, Stonebrook Private Inc. bought a new stake in shares of Pfizer during the third quarter worth approximately $208,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Finally, Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $31.92.

Remove Ads

Pfizer Price Performance

Shares of PFE stock traded down $0.16 during trading hours on Thursday, reaching $25.05. The company's stock had a trading volume of 51,260,038 shares, compared to its average volume of 36,807,599. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a market capitalization of $142.08 billion, a price-to-earnings ratio of 17.77, a PEG ratio of 0.64 and a beta of 0.61. The firm's 50 day simple moving average is $26.12 and its 200-day simple moving average is $26.98.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was up 24.7% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.